FibroGen Inc (NASDAQ:FGEN) shares were up 6.6% during trading on Tuesday . The company traded as high as $37.64 and last traded at $37.46. Approximately 1,332,317 shares were traded during mid-day trading, an increase of 76% from the average daily volume of 757,020 shares. The stock had previously closed at $35.14.

A number of research analysts have recently commented on FGEN shares. Stifel Nicolaus started coverage on shares of FibroGen in a report on Monday, February 11th. They issued a “buy” rating and a $71.00 price target on the stock. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 22nd. ValuEngine lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 14th. Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Friday, March 8th. Finally, TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a research report on Friday, March 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. FibroGen has a consensus rating of “Hold” and a consensus target price of $68.50.

The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -37.12 and a beta of 1.60.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.15. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.71%. The company had revenue of $23.90 million for the quarter, compared to the consensus estimate of $20.44 million. During the same quarter in the prior year, the company earned ($0.50) EPS. FibroGen’s quarterly revenue was down 25.1% on a year-over-year basis. On average, research analysts expect that FibroGen Inc will post -0.97 earnings per share for the current year.

In related news, CEO Thomas B. Neff sold 18,400 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $46.81, for a total value of $861,304.00. Following the transaction, the chief executive officer now owns 2,550,176 shares in the company, valued at approximately $119,373,738.56. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction that occurred on Wednesday, February 20th. The stock was sold at an average price of $57.41, for a total transaction of $2,275,502.76. Following the completion of the transaction, the chief executive officer now owns 2,658,056 shares in the company, valued at approximately $152,598,994.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 271,427 shares of company stock worth $14,084,728. 8.96% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlueMountain Capital Management LLC grew its stake in FibroGen by 736.1% in the 1st quarter. BlueMountain Capital Management LLC now owns 151,576 shares of the biopharmaceutical company’s stock valued at $8,238,000 after acquiring an additional 133,446 shares during the period. Perceptive Advisors LLC acquired a new stake in FibroGen in the 1st quarter valued at $506,000. Ladenburg Thalmann Financial Services Inc. grew its stake in FibroGen by 15.9% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,756 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 515 shares during the period. Morgan Stanley grew its stake in FibroGen by 48.1% in the 1st quarter. Morgan Stanley now owns 385,887 shares of the biopharmaceutical company’s stock valued at $20,973,000 after acquiring an additional 125,357 shares during the period. Finally, Metropolitan Life Insurance Co NY grew its stake in FibroGen by 172.7% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 66,579 shares of the biopharmaceutical company’s stock valued at $4,790,000 after acquiring an additional 42,166 shares during the period. 66.31% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Marea Informative and is the property of of Marea Informative. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.mareainformativa.com/news/2019/05/16/fibrogen-fgen-trading-up-6-6.html.

About FibroGen (NASDAQ:FGEN)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: How is Preferred Stock Different from Common Stock?

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.